As of November 9, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Aligos Therapeutics, Inc. The largest reported stake is Lawrence M. Blatt's, at 5.6%. 9 filings are on record since August 12, 2025 (Schedule 13D, June 24, 2026).
Sell to companies like Aligos Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Lawrence M. Blatt · Sole voting: 316,228 · Shared voting: 0 · Sole dispositive: 316,228 · Shared dispositive: 0 · SCHEDULE 13D, 2026-06-24
- · Holder: Woodline Partners LP · Percent: 4.4% · SCHEDULE 13G/A
- · Holder: Lawrence M. Blatt · Percent: 5.1% · SCHEDULE 13G
- · Holder: Woodline Partners LP · Percent: 5.4% · SCHEDULE 13G/A
- · Holder: Sio Capital Management, LLC · Percent: 5.46% · SCHEDULE 13G/A
Aligos Therapeutics, Inc. has 9 Schedule 13D or 13G filings on record since 2025-08-12. 2 holders' latest filing reports 5% or more of common stock, par value, $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 5.6% | 316,228 | SCHEDULE 13D, 2026-06-24 | 2026-06-16 | |
| Sio Capital Management, LLC | 5.46% | 335,937 | SCHEDULE 13G/A, 2026-02-11 | 2025-12-31 |
| Woodline Partners LP | 4.4% | 239,362 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Adage Capital Management, L.P. | 3.9% | 210,000 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
Holding shares or following this stake? See who's behind Aligos Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Aligos Therapeutics, Inc. and the records around it.
Aligos Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Sio Capital Management, LLC also filed stake reports on 9 other companies: Enveric Biosciences, Inc. (Nov 2026), Adagio Medical Holdings, Inc. (Jul 2026), PMV Pharmaceuticals, Inc. (Jul 2026)
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- Adage Capital Management, L.P. also filed stake reports on 136 other companies: ACP Holdings Acquisition Corp. (Aug 2026), AmperCap Acquisition Company (Aug 2026), Aura Biosciences, Inc. (Aug 2026)
Watch Aligos Therapeutics, Inc.
Get an email when Aligos Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aligos Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Aligos Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aligos Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Lawrence M. Blatt | 316,228 | 0 | 316,228 | 0 | SCHEDULE 13D, 2026-06-24 |
The latest filing identifies Aligos Therapeutics, Inc. by CUSIP 01626L204 and gives its principal executive office as One Corporate Drive, 2nd Floor, South San Francisco, CA 94080 (SCHEDULE 13D, 2026-06-24).
Source of funds (Item 3)
The Reporting Person acquired (approximately on a post-split basis) (i) 10,922 shares of Common Stock acquired indirectly by certain entities in connection with the conversion of preferred stock on October 20, 2020, in connection with the Issuer's initial public offering, and (ii) 24,411 shares of Common Stock and warrants exercisable for 12,206 shares of Common Stock for cash consideration of $499,999.95 in a private placement from the Issuer on October 25, 2023.Lawrence M. Blatt, SCHEDULE 13D, 2026-06-24
Purpose of Transaction (Item 4)
Lawrence M. Blatt
General The Reporting Person intends to review his investments in the Issuer on a continuing basis. Any actions the Reporting Person might undertake will be dependent upon the Reporting Person's review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments. The Reporting Person may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. The Reporting Person may also enter into financial instruments or other agreements with institutional or other counterparties that would increase or decrease the Reporting Person's economic exposure with respect to their investment in the Issuer, which instruments or agreements may or may not affect the Reporting Person's beneficial ownership in securities of the Issuer. In addition, the Reporting Person, in his positions as President, Chief Executive Officer and a director of the Issuer, may engage in discussions with management, the Issuer's board of directors (the "Board"), other securityholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary …The first part of Item 4 of the SCHEDULE 13D filed 2026-06-24; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Adage Capital Management, L.P. | 3.9% | SCHEDULE 13G/A |
| 2025-08-13 | Sio Capital Management, LLC | 5.49% | SCHEDULE 13G |
| 2025-08-14 | Woodline Partners LP | 9.8% | SCHEDULE 13G/A |
| 2025-11-14 | Woodline Partners LP | 8.7% | SCHEDULE 13G/A |
| 2026-02-11 | Sio Capital Management, LLC | 5.46% | SCHEDULE 13G/A |
| 2026-02-17 | Woodline Partners LP | 5.4% | SCHEDULE 13G/A |
| 2026-05-15 | Woodline Partners LP | 4.4% | SCHEDULE 13G/A |
| 2026-05-15 | Lawrence M. Blatt | 5.1% | SCHEDULE 13G |
| 2026-06-24 | Lawrence M. Blatt | 5.6% | SCHEDULE 13D |
Questions about who owns Aligos Therapeutics, Inc.
Who owns Aligos Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Aligos Therapeutics, Inc.: Lawrence M. Blatt (5.6%, Schedule 13D, filed 2026-06-24) and Sio Capital Management, LLC (5.46%, Schedule 13G/A, filed 2026-02-11).
Who are the largest shareholders of Aligos Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Aligos Therapeutics, Inc. on this page are Lawrence M. Blatt (5.6%) and Sio Capital Management, LLC (5.46%).
When did Lawrence M. Blatt buy into Aligos Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lawrence M. Blatt on this page is the Schedule 13G, filed 2026-05-15, reporting 5.1%; its latest, Schedule 13D filed 2026-06-24, reports 5.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Aligos Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 28, 2025 | Form D, private offering | $105M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Aligos Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.